The loss of Denali Therapeutics under GAAP for 6 months of 2020 amounted to $115.521 million, an increase of 18.7% compared to $97.329 million in the previous year. Revenues increased by 12.5% to $9,451 million compared to $8,402 million a year earlier.
The loss of Denali Therapeutics under GAAP for 6 months of 2020 amounted to $115.521 million, an increase of 18.7% compared to $97.329 million in the previous year. Revenues increased by 12.5% to $9,451 million compared to $8,402 million a year earlier. 
denalitherapeutics.com
English (US) 